Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

Video

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia (ALL).

Several different CAR T-cell products are examining ways to target CD19, says Park. For example, one product is a single-chain variable fragment that targets CD19. Preliminary data have been reported with the product in pediatric patients and it has been shown to result in a lower rate of cytokine release syndrome, says Park. If this study is further validated then that may present a safer option for adult patients with ALL.

Another CAR T-cell product is an allogeneic, off-the-shelf therapy, adds Park. Challenges exist with getting adult patients with aggressive disease autologous CAR T-cell products or generating T cells from these patients. To this end, off-the-shelf donor-derived CAR T-cell products are being investigated. Preliminary data with such products have been presented in the past, but an ongoing international study is evaluating the efficacy of this approach in a larger patient population, explains Park.

Additionally, ongoing studies are examining bispecific CAR T cells that are targeting CD19 and CD22 at the same time. The rationale for this approach is to reduce the rate of CD19-negative relapse by targeting 2 antigens simultaneously. The final data from this research are greatly anticipated, says Park. Other ongoing clinical studies are examining the efficacy of CAR T-cell therapies with the ultimate goal of providing safer and more effective products to adult patients with ALL; this continues to be a critical unmet need, concludes Park.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.